CHOSA Oncology – executive interview

CHOSA Oncology – executive interview

Chosa — 2 videos in collection

More on this equity

In this video we speak with Peter Buhl Jensen, CEO of CHOSA Oncology, and Claus Frisenberg, the company’s CFO. Chosa is a Scandinavian biotechnology company focused on the development of its proprietary drug response predictor (DRP). In the interview, Peter and Claus cover how the DRP helps stratify cancer patients who are most likely to respond to platinum chemotherapy, the data that Chosa has acquired to support its application in various cancer types, and the potential to use it in combination regimens with an immunotherapy partner. Peter and Claus also outline Chosa’s regulatory and commercial strategy, as well as key catalysts and milestones to watch out for over the next 12 months.


You may also be interested in these:

Healthcare

Executive interview - RhoVac